Psychedelics

From the unique challenges of treating physician-patients to updates on MDMA and psilocybin research and access, here are highlights from the week in Psychiatric Times.

A new bill, the Breakthrough Therapies Act, would encourage the reclassification of MDMA and psilocybin from schedule I to schedule II drugs.

The second of a phase 3 study examining MDMA-AT just completed its final participant visit.

A single dose of psilocybin could help patients with treatment-resistant depression, according to a new study.

Classic psychedelic research is rapidly expanding...

Vol. 39, Issue 9 covers the latest in psychedelics research and development in psychiatry.

In a well-blinded study, researchers investigated and directly compared the acute effects of LSD and psilocybin in healthy participants.

How can a robust understanding of the altered-state experience drive the development of therapeutic frameworks that are designed around that experience?

The underlying neural mechanisms identified may help clinicians better understand ketamine response in human patients.

This new study is evaluating how effective psychedelics can be in the treatment of binge eating disorder.

Numinus' Chief Clinical Officer shares resources about the potential use of ketamine in psychiatry.

The first patient has been dosed in the phase 2b dose-optimization trial of a pharmaceutically optimized form of LSD for the treatment of generalized anxiety disorder.

This is the extra table for "Interest Grows in Treatment of Mood Disorders by Classic Psychedelics."

One researcher shares his evidence for the usage of psilocybin in psychiatry.

The resistance against "magic mushrooms"—is it justified?

We have an urgent need for new and improved treatment options for depression—are psychedelic medications the answer?

Treatments alter the neural processes underlying SAD symptoms.

How can psychedelic research incorporate disability inclusion into future work?

What are your thoughts on psychedelics?

Research is underway to make psychedelics agents a treatment option for psychiatric disorders.

Drug comparison has significant implications for dose- and substance-dependence.

Welcome to the psychedelic renaissance.

Psychedelics: returning hope to veterans with PTSD.

Here's why psychedelics might be a valuable addition to mental health treatment.